Loading...
XNAS
HALO
Market cap6.65bUSD
May 21, Last price  
53.93USD
1D
0.90%
1Q
-6.11%
Jan 2017
445.85%
Name

Halozyme Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:HALO chart
No data to show
P/E
14.96
P/S
6.55
EPS
3.60
Div Yield, %
Shrs. gr., 5y
-2.16%
Rev. gr., 5y
38.95%
Revenues
1.02b
+22.44%
127,209981,7463,799,5218,764,13913,671,30513,624,11556,086,43642,325,22654,799,44775,334,000135,057,000146,691,000316,613,000151,862,000195,992,000267,594,000443,310,000660,116,000829,253,0001,015,324,000
Net income
444m
+57.71%
-13,275,373-14,751,986-23,896,183-48,654,199-58,360,523-53,241,650-19,769,851-53,552,002-83,478,551-68,375,000-32,231,000-103,023,00062,971,000-80,330,000-72,240,000129,085,000402,710,000202,129,000281,594,000444,091,000
CFO
479m
+23.29%
-12,996,2297,079,563-147,660-35,373,864-40,148,265-45,385,506-34,350,425-64,329,296-49,339,479-47,518,000-37,083,000-50,383,000134,053,000-49,500,000-85,423,00055,454,000299,440,000240,110,000388,571,000479,064,000
Earnings
Aug 04, 2025

Profile

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
IPO date
Jan 30, 2003
Employees
393
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,015,324
22.44%
829,253
25.62%
660,116
48.91%
Cost of revenue
238,465
268,724
205,911
Unusual Expense (Income)
NOPBT
776,859
560,529
454,205
NOPBT Margin
76.51%
67.59%
68.81%
Operating Taxes
113,041
66,735
46,789
Tax Rate
14.55%
11.91%
10.30%
NOPAT
663,818
493,794
407,416
Net income
444,091
57.71%
281,594
39.31%
202,129
-49.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
(250,000)
(394,504)
(185,952)
BB yield
4.04%
7.95%
2.32%
Debt
Debt current
13,334
Long-term debt
1,505,798
1,531,445
1,527,554
Deferred revenue
2,253
Other long-term liabilities
54,758
37,720
45,905
Net debt
909,724
1,195,445
1,177,594
Cash flow
Cash from operating activities
479,064
388,571
240,110
CAPEX
(10,696)
(15,294)
(4,810)
Cash from investing activities
(262,723)
(96,909)
(487,005)
Cash from financing activities
(218,861)
(407,987)
362,371
FCF
612,454
454,291
239,513
Balance
Cash
596,074
336,000
362,794
Long term investments
500
Excess cash
545,308
294,537
330,288
Stockholders' equity
363,821
81,399
142,430
Invested Capital
1,560,556
1,539,377
1,581,626
ROIC
42.83%
31.64%
29.98%
ROCE
40.37%
34.58%
26.35%
EV
Common stock shares outstanding
129,424
134,197
140,608
Price
47.81
29.36%
36.96
-35.04%
56.90
41.51%
Market cap
6,187,761
24.76%
4,959,921
-38.01%
8,000,595
35.54%
EV
7,097,485
6,155,366
9,178,189
EBITDA
858,171
645,385
503,846
EV/EBITDA
8.27
9.54
18.22
Interest
18,095
18,762
16,947
Interest/NOPBT
2.33%
3.35%
3.73%